Form 4: Moleculin Biotech CEO Walter Klemp Reports Stock Transactions
SEC Form 4 Filing
Walter Klemp, CEO and President of Moleculin Biotech, reports the vesting of restricted stock units and associated tax withholding.
Summary
- On June 20, 2024, Walter Klemp, CEO and President of Moleculin Biotech, reported transactions involving the company's common stock.
- Klemp acquired 3,750 shares of common stock through the vesting of restricted stock units.
- 914 shares were withheld for payment of taxes upon the vesting of these restricted stock unit awards at a price of $3.78.
- Following these transactions, Klemp directly owns 49,493 shares of Moleculin Biotech common stock and 123,124 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions reported may have a minor impact on shareholders due to the change in the CEO's holdings.
Key Dates
| Date | Description |
|---|---|
| 06/20/2022 | Reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 06/20/2024 | Date of stock transactions: vesting of restricted stock units and tax withholding. |
| 06/21/2024 | Date of signature for the Form 4 filing. |
Keywords
Moleculin Biotech, MBRX, Walter Klemp, CEO, Form 4, Stock Transaction, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.